Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice

Stroke

Volumn 32, Issue 4, 2001, Pages 980-985

  Amin Hanjani, Sepideh ^a   Stagliano, Nancy E ^a   Yamada, Masaru ^a   Huang, Paul L ^a   Liao, James K ^a   Moskowitz, Michael A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cerebral ischemia; Endothelial nitric oxide synthase; HMG CoA reductase inhibitors; Mice

Indexed keywords

AMPHETAMINE; CARBON 14; CHOLESTEROL; COMPACTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PROTEIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CEREBRAL ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORBIDITY; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; STROKE;

EID: 0035073930     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.str.32.4.980     Document Type: Article

References (24)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S)
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
5. Simvastatin, an HMG-coenzyme reductase inhibitor, improves endothelial function within 1 month
6. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibfinolytic activity in rat aortic endothelial cells
7. Inhibition of 3-hyroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
8. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
9. Hypertension in mice lacking the gene for endothelial nitric oxide synthase
10. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase
11. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion
12. Strain related differences in susceptibility to transient forebrain ischemia in SV-129 and C57Black/6 mice
13. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment
14. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
15. L-arginine dilates rat pial arterioles by nitric oxide-dependent mechanisms and increases blood flow during focal cerebral ischemia
16. Blood flow-dependent functional recovery in a rat model of focal cerebral ischemia
17. Reduction of focal cerebral ischemic damage by delayed treatment with nitric oxide donors
18. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation
19. Inducible nitric oxide synthase is an endogenous neuroprotectant after traumatic brain injury in rats and mice
20. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
21. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin
22. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors
23. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
24. Neuroprotection mediated by changes in the endothelial actin cytoskeleton